Interneuron deal

IPIC's Transcell Technologies Inc. subsidiary and Biocure Ltd. (Aberdeen, Scotland) will develop oligosaccharides to treat cancer. Transcell will use its carbohydrate chemistry to synthesize more potent analogs of Biocure's lead drug candidate, MT2, a small molecule carbohydrate derivative. Transcell (Princeton, N.J.) will also be responsible for characterizing the key structural features important to the activity of MT2. Biocure will fund research for one year. ...